News
Archives
- 2021
- 2020
- Oct (1)
- Jul (1)
- Apr (1)
- 2019
- Dec (1)
- Oct (1)
- Jul (1)
- Apr (1)
- Jan (1)
- 2018
- Oct (1)
- Jul (1)
- Apr (1)
- Jan (1)
- 2017
- Oct (1)
- Jul (1)
- Apr (1)
- Jan (1)
- 2016
- Oct (1)
- Apr (2)
- Jan (1)
- 2015
- 2014
- 2013
- Oct (1)
- Jul (1)
-
Apr (5)
- First investigator meeting for our new North Asia sites for the first time
- The National Cancer Institute (U.S) has recently labelled Aspirin in Colorectal Cancer as one of the most provocative questions in cancer
- We congratulate Dr Tham and team, and team from Sixth Affiliated Hospital
- Zhejiang and Zhongshan hospitals obtained IRB approval
- PIK3CA subgroup analysis included as a new secondary endpoint
- Jan (2)
- 2012
- Oct (2)
- Apr (1)
- Jan (1)
- 2011
- Oct (1)
- Jul (1)
- Apr (1)
1 Oct 2014
Congratulations to Sir Charles Gairdner Hospital, Calvary Mater Newcastle Hospital and Orange Health Service/Central West Cancer Services who recruited their first patients in 3rd Quarter 2014. They are the very first Australia Sites with randomized subjects for ASCOLT.
11 Australia sites are activated last quarter: Sir Charles Gairdner Hospital, The Tweed Hospital, Calvary Mater Newcastle Hospital, Newcastle Private Hospital, St John of God Subiaco, Orange Health Service/Central West Cancer Services, Royal Hobart Hospital, Northwest Cancer Centre/Tamworth Hospital, Townsville Hospital, Port Macquarie Base Hospital North, Ballarat Regional Integrated Cancer Centre Coast Cancer Institute.
3rd Quarter 2014 Site Activation and Randomization